| Dataset | GAD Gene-Disease Associations |
| Category | disease or phenotype associations |
| Type | disease |
| Description | A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.|Tumors or cancer of the LIVER.|A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation. --2002|A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation. (Experimental Factor Ontology, EFO_0000182) |
| Similar Terms | |
| Downloads & Tools |
47 genes associated with the disease hepatocellular carcinoma in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.
| Symbol | Name |
|---|---|
| ALDOB | aldolase B, fructose-bisphosphate |
| APC | adenomatous polyposis coli |
| BTRC | beta-transducin repeat containing E3 ubiquitin protein ligase |
| CABIN1 | calcineurin binding protein 1 |
| CCND1 | cyclin D1 |
| CD34 | CD34 molecule |
| CD80 | CD80 molecule |
| CD81 | CD81 molecule |
| CDKN1B | cyclin-dependent kinase inhibitor 1B (p27, Kip1) |
| CXCL10 | chemokine (C-X-C motif) ligand 10 |
| EGF | epidermal growth factor |
| FGL1 | fibrinogen-like 1 |
| GRAP2 | GRB2-related adaptor protein 2 |
| GSTM1 | glutathione S-transferase mu 1 |
| HLA-DPB1 | major histocompatibility complex, class II, DP beta 1 |
| HLA-DQA1 | major histocompatibility complex, class II, DQ alpha 1 |
| HLA-DQB1 | major histocompatibility complex, class II, DQ beta 1 |
| HLA-DRB1 | major histocompatibility complex, class II, DR beta 1 |
| IFI27 | interferon, alpha-inducible protein 27 |
| IFNAR1 | interferon (alpha, beta and omega) receptor 1 |
| IFNAR2 | interferon (alpha, beta and omega) receptor 2 |
| IL12RB1 | interleukin 12 receptor, beta 1 |
| IL18 | interleukin 18 |
| IL18R1 | interleukin 18 receptor 1 |
| IL1B | interleukin 1, beta |
| IL2RB | interleukin 2 receptor, beta |
| IL4 | interleukin 4 |
| LTBP2 | latent transforming growth factor beta binding protein 2 |
| MASP2 | mannan-binding lectin serine peptidase 2 |
| MBL2 | mannose-binding lectin (protein C) 2, soluble |
| MT1X | metallothionein 1X |
| MX1 | MX dynamin-like GTPase 1 |
| NFKB1 | nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
| OGG1 | 8-oxoguanine DNA glycosylase |
| PLA2G12B | phospholipase A2, group XIIB |
| PTK2 | protein tyrosine kinase 2 |
| RB1 | retinoblastoma 1 |
| SPARC | secreted protein, acidic, cysteine-rich (osteonectin) |
| STAT3 | signal transducer and activator of transcription 3 (acute-phase response factor) |
| STAT5A | signal transducer and activator of transcription 5A |
| TERF1 | telomeric repeat binding factor (NIMA-interacting) 1 |
| TERF2 | telomeric repeat binding factor 2 |
| TGFB1 | transforming growth factor, beta 1 |
| TP53 | tumor protein p53 |
| UGT1A6 | UDP glucuronosyltransferase 1 family, polypeptide A6 |
| UGT1A7 | UDP glucuronosyltransferase 1 family, polypeptide A7 |
| UGT1A9 | UDP glucuronosyltransferase 1 family, polypeptide A9 |
